APA

Sondhi D., Peterson D. A., Giannaris E. L., Sanders C. T., Mendez B. S., De B., Rostkowski A. B., Blanchard B., Bjugstad K., Sladek J. R., Redmond D. E., Leopold P. L., Kaminsky S. M., Hackett N. R. & Crystal R. G. (20060301). AAV2-mediated CLN2 gene transfer to rodent and non-human primate brain results in long-term TPP-I expression compatible with therapy for LINCL. : Gene therapy.

Chicago

Sondhi D, Peterson D A, Giannaris E L, Sanders C T, Mendez B S, De B, Rostkowski A B, Blanchard B, Bjugstad K, Sladek J R, Redmond D E, Leopold P L, Kaminsky S M, Hackett N R and Crystal R G. 20060301. AAV2-mediated CLN2 gene transfer to rodent and non-human primate brain results in long-term TPP-I expression compatible with therapy for LINCL. : Gene therapy.

Harvard

Sondhi D., Peterson D. A., Giannaris E. L., Sanders C. T., Mendez B. S., De B., Rostkowski A. B., Blanchard B., Bjugstad K., Sladek J. R., Redmond D. E., Leopold P. L., Kaminsky S. M., Hackett N. R. and Crystal R. G. (20060301). AAV2-mediated CLN2 gene transfer to rodent and non-human primate brain results in long-term TPP-I expression compatible with therapy for LINCL. : Gene therapy.

MLA

Sondhi D, Peterson D A, Giannaris E L, Sanders C T, Mendez B S, De B, Rostkowski A B, Blanchard B, Bjugstad K, Sladek J R, Redmond D E, Leopold P L, Kaminsky S M, Hackett N R and Crystal R G. AAV2-mediated CLN2 gene transfer to rodent and non-human primate brain results in long-term TPP-I expression compatible with therapy for LINCL. : Gene therapy. 20060301.